Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | OXER1 | Q8TDS5 | 8/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27753559 | 0.85 | PPARG (0.40) | PPARGOXER1 | |
| SCHEMBL7072559 | 0.75 | KMT2A (0.47) | — | |
| SCHEMBL28341086 | 0.75 | PPARG (0.46) | PPARGOXER1 | |
| SCHEMBL7952849 | 0.74 | PPARG (0.42) | PPARGOXER1 | |
| SCHEMBL28436072 | 0.74 | PPARG (0.42) | PPARGOXER1 | |
| SCHEMBL7551690 | 0.69 | OXER1 (0.59) | PPARGOXER1 | |
| SCHEMBL15353453 | 0.68 | PPARG (0.38) | PPARGOXER1 | |
| SCHEMBL10413631 | 0.68 | TLR8 (0.49) | PPARGOXER1 | |
| SCHEMBL21359604 | 0.67 | L3MBTL1 (0.57) | PPARGOXER1 | |
| SCHEMBL14229188 | 0.67 | OXER1 (0.67) | PPARGOXER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405305-B2 | Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20050288321-A1 | Kinase inhibitors | ELI LILLY AND COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288321-A1 | Kinase inhibitors | ABL1, MAP3K20, MAP3K19 | PPARG 4140/4885OXER1 3769/4885NPC1 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.